AmySong Ph.D.


New York + 1.212.326.8374

Dr. Amy Song's legal experience extends across all aspects of patent law. Amy assists clients in patent preparation and worldwide patent prosecution; she also helps clients evaluate patentability, ensure freedom to operate, and perform due diligence reviews. Amy's experience further includes inter partes review (IPR) proceedings, Hatch-Waxman litigations, and Federal Circuit appeals. Amy has experience with a wide range of technologies, including CAR-T cell therapy, therapeutic antibodies, viral vaccines, oncolytic viruses, small molecule drugs, immunotherapies, and stem cell therapies.

Amy's representative experience includes patent procurement for a cancer research institute regarding cancer immunotherapies being developed in clinic; freedom to operate and patentability analysis for a major pharmaceutical company regarding therapeutic antibodies; due diligence review for a biopharmaceutical company in a deal involving a prostate cancer medicine; Hatch-Waxman litigation involving small molecule drugs; a Federal Circuit appeal involving a parental iron therapy; and IPRs involving dendritic cell vaccines.

Originally from China, Amy received her Ph.D. degree from Oregon State University. Her doctoral thesis studied the combined effects of food antioxidants, phytochemicals, and exercise on DNA damage and oxidative stress. She continued her research at Yale School of Medicine as a postdoctoral fellow. Her post-doctoral research focused on how the aging process and high-fat diets promoted the development of atherosclerosis. Amy also received medical and clinical training from Peking University School of Medicine. Amy has coauthored 18 scientific and legal articles, and her work has been cited by over 800 peer-reviewed articles.


  • NGM Bio develops global patent portfolio for therapeutic antibodies for the treatment of cancer and tumorsJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for therapeutic antibodies for the treatment of cancer and tumors, including NGM707, a dual ILT2/ILT4 antagonist antibody; NGM831, an ILT3 antagonist antibody; and NGM438, a LAIR1 antagonist antibody.